CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership

As bio/pharmaceutical development grows increasingly complex, industry collaboration remains critical to addressing the challenges of modern drug manufacturing, regulation, and global supply resilience. The agenda and speaker lineup for CPHI Frankfurt 2025 reflects this need as Informa Markets unveils a new Leadership Summit designed to unite decision-makers from across the global bio/pharmaceutical value chain (1).

Taking place Oct. 28–30, 2025, at Messe Frankfurt, the event will feature more than 260 expert speakers from regulatory bodies, biotech startups, manufacturing organizations, and supply chain leaders. The program will focus on the future of drug development, artificial intelligence (AI), digital transformation, and sustainability—key themes shaping how bio/pharmaceutical technologies are developed, scaled, and delivered worldwide (1–4).

“The 2025 event reflects not only the scale of innovation across pharma but also the sector’s need for connected leadership and diverse perspectives,” said Tara Dougal, event director for Informa Markets, in a press release (1). “Our speaker line-up represents a balance of experience and forward thinking, tackling the core challenges and opportunities facing pharma today.”

What key industry issues will the leadership summit address?

The Leadership Summit, sponsored by Ensera (formerly SteriPack), is a major addition to this year’s event. The summit will serve as a strategic forum for executive dialogue on topics such as pharmaceutical resilience, mergers and acquisitions, access to medicines, and the impact of geopolitical shifts on global supply chains.

These discussions are expected to resonate across the bio/pharmaceutical industry, for which managing risk and maintaining manufacturing continuity are central concerns. By emphasizing long-term strategy and policy alignment, the summit aims to bridge the gap between regulatory goals, commercial strategy, and the operational realities of global drug production.

What hot topics will the specialized tracks explore?

The conference’s seven content tracks will explore specialized areas critical to the evolution of pharmaceutical manufacturing and development and will include:

• Packaging and Device Innovation (Hall 8.0): Patient-centric packaging, connected devices, and regulatory strategies for combination products
• Future of Pharma and Ingredients (Hall 8.0): Advances in API design, digital chemistry, and modernization of regulatory pathways
• Next-Gen Bio (Hall 4.1): Challenges and solutions in scaling up biologics, cell and gene therapies, and messenger RNA platforms
• Clinical Innovation (Hall 6.1): Use of AI, digital endpoints, and decentralized trial models to improve patient recruitment and data reliability
• Manufacturing 5.0 (Hall 4.1): Smart factories, machine learning integration, and operational excellence in production
• Sustainable Futures (Hall 4.0): Strategies for low-emission manufacturing, circular pharma, and responsible sourcing
• Spotlight Stage (Hall 4.0): Focused updates on cleanroom technologies and sustainability in production.

According to Informa, each track was developed in collaboration with global partners, including IQVIA, Medicines for Europe, CEPI, Environmental Financial Consulting Group, and PSCI. The collaboration aims to ensure that the content reflects the latest data-driven insights and industry priorities (1).

The diversity of speakers includes subject matter experts from government, academia, and multinational biopharma enterprises and underscores CPHI Frankfurt’s role as a global forum for advancing bio/pharmaceutical technology. Through technical sessions and leadership discussions, the event aims to shape the dialogue around efficiency, sustainability, and digitalization across the full drug development lifecycle (1).

References

1. CPHI. CPHI Frankfurt 2025 Unveils Dynamic Speaker Line-Up and Launches New Leadership Summit. Press Release. Oct. 21, 2025.
2. Fu, C.; Chen, Q. The Future of Pharmaceuticals: Artificial Intelligence in Drug Discovery and Development. J. Pharm. Anal. 2025, 15 (8), 101248. DOI: 10.1016/j.jpha.2025.101248
3. Mustoe, C. L.; Turner, A. J.; Urwin, S. J.; et al. Quality by Digital Design to Accelerate Sustainable Medicines Development. Int. J. Pharm. 2025, 681, 125625. DOI: 10.1016/j.ijpharm.2025.125625
4. Jallat, F.; Morillon, G. The Rise of AI in Biopharmaceuticals: Uncovering the Environmental Cost and the Promise of Sustainable AI. ESCP Impact Paper No.2025-44-EN. 2025.